Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Pathology and Clinical Laboratory Medicine, |
RCV000191923 | SCV001438898 | pathogenic | Hereditary spastic paraplegia 50 | criteria provided, single submitter | clinical testing | ||
Institute of Human Genetics, |
RCV000191923 | SCV001443059 | pathogenic | Hereditary spastic paraplegia 50 | 2020-03-01 | criteria provided, single submitter | clinical testing | Review of the variants reported in Reuter et al., 2017, PMID: 28097321: PVS1,PM2,PM3,(PP1) |
Prevention |
RCV003390861 | SCV004111189 | pathogenic | AP4M1-related condition | 2022-12-20 | criteria provided, single submitter | clinical testing | The AP4M1 c.952C>T variant is predicted to result in premature protein termination (p.Arg318*). This variant was reported in individuals with autosomal recessive spastic tetraplegia (Tüysüz et al. 2014. PubMed ID: 24700674; Table S1, Monies et al. 2019. PubMed ID: 31130284; Table S2, Dong et al. 2020. PubMed ID: 32005694). This variant is reported in 0.00088% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/7-99703604-C-T). Nonsense variants in AP4M1 are expected to be pathogenic. This variant is interpreted as pathogenic. |
Center for Genomic Medicine, |
RCV000191923 | SCV004804977 | pathogenic | Hereditary spastic paraplegia 50 | 2024-03-17 | criteria provided, single submitter | research | |
Department Of Translational Genomics |
RCV000162190 | SCV000196476 | likely pathogenic | Global developmental delay; Hypoplasia of the corpus callosum; Microcephaly; CNS hypomyelination; Brain atrophy | 2014-12-01 | no assertion criteria provided | research | |
OMIM | RCV000191923 | SCV000246146 | pathogenic | Hereditary spastic paraplegia 50 | 2014-07-01 | no assertion criteria provided | literature only | |
Diagnostic Laboratory, |
RCV001529845 | SCV001744025 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV001529845 | SCV001958789 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Yale Center for Mendelian Genomics, |
RCV001849324 | SCV002106861 | likely pathogenic | Spastic paraplegia | 2020-10-01 | no assertion criteria provided | literature only |